At the news
? BEARISHIMPACT 6/10 PRESS-RELEASE filed Jul 30, 2026 at 16:05 ET
Penumbra reported Q2 2026 revenue of $390.0M (+14.9% YoY), in line with consensus, but EPS of $0.88 (diluted) missed the $1.18 consensus estimate by 25.4%. The company is not providing guidance due to the pending acquisition by Boston Scientific (BSX), which introduces deal-closing risk and removes the typical earnings catalyst. The EPS miss is significant, but the acquisition premium likely caps downside.
- Revenue of $390.0M, +14.9% YoY, in line with $390.1M consensus
- Diluted EPS of $0.88, missed consensus of $1.18 by 25.4%
- Net income of $34.8M, down from $45.3M in Q2 2025
- Global thrombectomy revenue $259.0M (+12.5% YoY); embolization & access $131.1M (+20.0% YoY)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access